JAK/TYK2

      Dr. Tom Appleton and Dr. Peter Nash Highlight OA and PsA Studies
      4 years 11 months ago

      Dr. Janet Pope interviews Dr. Tom Appleton and Dr. Peter Nash about several osteoarthritis and psoriatic arthritis studies presented at the 2020 ACR annual meeting.

      Vaccination with Shingrix: Does it work for patients on JAKi?
      4 years 11 months ago

      Dr. Jeffrey Curtis examines abstracts #1997 and #0452 presented at the ACR 2020 annual meeting.

      RT @Janetbirdope: What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumato

      Janet Pope Janetbirdope

      4 years 11 months ago
      What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
      RT @DrMiniDey: Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadaciti

      Mrinalini Dey DrMiniDey

      4 years 11 months ago
      Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor -HZ events more common in patients taking 30mg vs 15mg -HZ more common in UPA vs those taking ADA+MTX & MTX Abs#2002 #ACR20 @RheumNow https://t.co/tQ03wBueW5
      RT @KDAO2011: Which JAKi will you use after MTX failure? #acr20 @rheumnow

      k dao KDAO2011

      4 years 11 months ago
      Which JAKi will you use after MTX failure? #acr20 @rheumnow
      RT @RADoctor: Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 2

      Jeffrey Curtis RADoctor

      4 years 11 months ago
      Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
      RT @doctorRBC: Upadacitinib vs. Adalimumab vs. PBO in PsAPhase 3 RCT⬇️MSK symptoms, PsO, function, pain, fatigue,

      Robert B Chao, MD doctorRBC

      4 years 11 months ago

      Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

      RT @DrMiniDey: Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis pati

      Mrinalini Dey DrMiniDey

      4 years 11 months ago
      Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors - Most RA pts on JAKi have sufficient antibody response to HZ vaccine - Acceptable safety profile Abs#1997 #ACR20 @RheumNow https://t.co/8HWAIwOATD
      RT @RichardPAConway: Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients tre

      Richard Conway RichardPAConway

      4 years 11 months ago
      Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
      Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial o

      Dr. John Cush RheumNow

      4 years 11 months ago
      Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial of 203 PsA patients showed wk 16 significant improvement in ACR20/50/70, enthesitis, SPARC scores. #ACR20 Abstr#L03 https://t.co/LGokmmlyrc
      RT @RichardPAConway: Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greate

      Richard Conway RichardPAConway

      4 years 11 months ago
      Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn
      RT @ejdein1: SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general hea

      Eric Dein ejdein1

      4 years 11 months ago
      SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general health over ABA. Abst#1728 @RheumNow #ACR20. ABA better if a safety concern, but this is more evid to go for UPA
      RT @DrPetryna: @rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% &

      Olga Petryna DrPetryna

      4 years 11 months ago
      @rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i
      RT @KDAO2011: No need to stop Tofa w/the flu?
      👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar

      k dao KDAO2011

      4 years 11 months ago
      No need to stop Tofa w/the flu? 👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB. 👉Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar. Abstr#L04 #ACR20 @rheumnow #ACRBest https://t.co/rZXKRVl7uK
      A New Pathway in Psoriatic Arthritis: Dr. Eric Ruderman
      4 years 11 months ago

      Dr. Ruderman discusses a new pathway - the use of deucravacitinib - for the treatment of psoriatic arthritis (abstracts L03) at the ACR 2020 annual meeting.

      Catch up on Conference Podcasts

      ×